Key facts
- It has raised $22.5M across 1 recorded rounds; the latest was Early Stage VC ($22.5M) in Mar 2026.
- Notable investors include LDV Partners, Eshelman Ventures.
- Pacegenix has filed 1 Form D with the SEC, most recently Mar 2026 ($22.5M sold to 15 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Pacegenix
Funding rounds
1 roundsAbout Pacegenix
Developer of precision cardiology therapeutics designed to treat heart rhythm disorders and improve outcomes in patients with complex arrhythmias. The company develops targeted cardiovascular drug candidates focused on rhythm and rate control for patients with conditions such as atrial fibrillation, hypertrophic cardiomyopathy, inappropriate sinus tachycardia, and heart failure-related arrhythmias, enabling patients with complex heart rhythm disorders access targeted therapies that improve cardiac function and quality of life.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2024
- Website
- pacegenix.com/
- Ownership
- Privately Held (backing)
Pacegenix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pacegenix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pacegenix in its N-PORT filings yet. We sweep new filings monthly.